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One interpretation the authors offer is that there may be
estrous variations in colonic visceral pain, with pain being
greatest in proestrus. However, other interpretations are
possible. Another relevant finding in these two studies was
that colonic pressures induced by distension did not vary
with estrous stage. What this result means is that, during
proestrus, smaller fecal boli would trigger defecation.
Proestrus is the reproductive stage in which rats are
fertile and most easily aroused by hindquarter tactile stimu-
lation. Thus, it may be that the rat’s similarly more sensitive
visceromotor and colonic responses to colonic distension
during proestrus promote emptying of the colon to facili-
tate successful fertilization during copulation. Whether
there would be an accompanying change in colonic pain is
unclear, but seems unlikely. Supporting this interpretation
is the finding that cardiovascular responses showed no
estrous increases during proestrus. Thus, the clinical rele-
vance of these findings might be more applicable to gastro-
intestinal motility issues (Wald et al. 1981) than to colonic
pain. But, of course, as discussed above in section R9.3, all
of these conclusions might change under conditions of
colonic pathophysiology (Giamberardino et al. 1997).
R9.5. Sex hormones. It is often a knee-jerk response to
assume that any sex or estrous/menstrual stage variations in
an entity are due to sex hormones. As discussed in section
R9.3 above, this assumption is clearly unwarranted until
further study has demonstrated it. Although the issue of sex
hormones and pain is an important one, few, if any, human
studies have focused on it.
Finally, however, a recent study has directed its full
attention on the impact of hormones on a pathophysiologi-
cal pain condition in humans. In an elegant and well-
controlled epidemiological study based on automated phar-
macy records of women enrolled in a large health mainte-
nance organization in the northwestern United States,
LeResche and colleagues (1997) found that the odds of
having temporomandibular disorder pain were increased
by approximately 20% and 30%, respectively, in young
women who used oral hormone contraceptives and post-
menopausal women who used estrogen (or estrogen and
progestin) replacement therapies. For the postmenopausal
women, these odds increased with increased doses of
estrogen. No clearcut increased risk was observed with
progestin use.
Although an immediate conclusion from these findings
might be that women and their doctors should add an
increased risk of temporomandibular pain to their list of
cons when weighing the pros and cons of oral contraceptive
or estrogen replacement therapy, the authors themselves
are rightly very cautious and self-critical in their assessment
of the implications of their findings. They make no state-
ments on the clinical applicability of their findings. How-
ever, they rightly point out the provocativeness of their
findings and provide a long list of future studies to test how
generalizable their findings are to other populations and
other painful disorders. If their findings do prove generaliz-
able, then understanding the mechanisms that give rise to this
increased risk will certainly have a powerful clinical impact.
In sum, these previous five sections not only provide
convincing arguments that sex is one of the potent factors
underlying pain, they also indicate that progress is well
underway toward a better understanding of how to apply
the information clinically.
R10. Conclusions [Kupers, Binik, Rollman, and
Gijsbers & Niven]
Are sex differences relevant to mechanisms of persistent
pain and its treatment? Kupers, via Molie`re, provides a clear
answer: “oui et non.” I here provide a less clear one: “yes.”
Gijsbers & Niven remind us that our conclusions
should be based “not on the insignificance of sex differ-
ences in behaviour and perception but on their complexity,”
and that only through further study will we “come to
understand the extent to which individual differences in
suffering are dependent on generalisable sex differences.”
Rollman states that when it comes to caring for a single
human of either sex, we “need to base evaluation and
treatment upon individual reports rather than gender-
based stereotypes.” Binik points out that “pain and plea-
sure researchers have something to learn from each other.”
I cannot say it any better.
Pains, brains, and opium
Anthony H. Dickenson
Department of Pharmacology, University College London, London WC1E
6BT, UK. anthony.dickenson@ucl.ac.uk
Abstract: In this response, I discuss the roles of the peripheral afferent drive in the maintenance of persistent pain, the concept of pre-
emptive analgesia and the importance of the brain, the detailed involvement of which in pain is far less well understood compared to the
events in the spinal cord. A comparison of pain to other sensory modalities is then made together with a discussion of learning and pain.
These facets of pain are discussed in the light of treatment strategies for this condition.
R1. Introduction 
First and foremost, I wish to say how much I enjoyed and
appreciated the comments. One of the great joys of science
is communication, and these open and frank views, with
their benevolent and constructive comments, illustrate
the ways in which advances in a subject can occur via
interactions as well as by research. It should also be
noted that the comments are from both scientists and
clinicians. The remarkable advances in the understanding
of pain transmission and control that have arisen over the
last decade are in no small part due to dialogue and
interactions between these two groups. It is difficult to
imagine many other areas of neuroscience where science
and clinical medicine are so well integrated. However, we
are still using opium and derivatives of the bark of the
willow to combat pain – it is perplexing that, given the
number of targets that there are for the control of pain,
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the pharmaceutical industry has not developed a single
novel analgesic.
R2. Pain starts in the periphery 
Where does one start when discussing pain? Logically,
where pain starts, and so to the periphery.
A theme that arises in a number of commentaries is the
relative role of peripheral activity and central hypersen-
sitivity in setting the level of pain transmission. Devor,
Gracely, and Cleland & Gebhart all raise this point. The
issues here are twofold: (1), whether central hypersen-
sitivity can occur in the absence of peripheral activity and
(2), the relative importance of peripheral and central activ-
ity in the generation of the final sensations.
Because both the above authors and I believe that central
hypersensitivity cannot occur in the absence of peripheral
activity (see sect. 7.1), the second point I feel is easily
handled. As peripheral activity will go nowhere without
central transmission and central hypersensitivity needs pe-
ripheral activity, the two are intimately linked. Thus block-
ing either would be effective. Which would be most effec-
tive? The actual levels of activity produced by each is one
issue. The points made by the three commentators are
important ones. Both Gracely and I discuss the effects of
combination therapy because, as pointed out by Gracely,
NMDA antagonists would only reduce the sensitized com-
ponents. Thus, I feel that an NMDA antagonist plus
morphine could be the most effective approach to pain
control with centrally acting agents, because spinal opioid
analgesia, by virtue of the predominant presynaptic actions
of opioid receptors in blocking primary afferent transmitter
release, would synergize with the postsynaptic reduction in
hypersensitivity produced by NMDA blocker (sect. 7.1).
The advantage here is that low doses of each could be used
and so reduce side-effect liability.
This approach could provide excellent pain relief in
situations of tissue damage. A problem is that in neuro-
pathic states, opioids are less effective and there are as yet
no studies in humans on the effects of this combination
after nerve injury. Here I refer to the commentary of
Backonja, who agrees with the point I made that morphine
needs to be tried in neuropathic pain patients and the dose
escalated to a maximum before other approaches are tried.
Jadad et al. have shown that some neuropathic pain patients
do well on opioids. The commentary of Marchettini et al.
on the differentiation of neuropathic syndromes and that on
the fact that opioids can work in some situations reinforces
these points and lends further support to the idea that
lumping together all the varieties of nerve damage is
counterproductive. Subdivided neuropathic syndromes
may reveal certain symptoms that respond to opiates. Note
also (sect. 9) that some measures of behaviour in animal
models of neuropathic pain respond to morphine whereas
others do not. The same point is made by Siddall, to whose
comments I will return later in the context of inhibitions.
It is also true that blocking the peripheral activity will be
equally efficient, as suggested by Devor, Gracely, and
Cleland & Gebhart. I entirely agree with Cleland &
Gebhart that the basic studies (paras. 7 and 8) suggesting
that hyperalgesia persists after nerve block may well be
flawed by technical problems. So, since we all agree on this
issue, what would be the best approach? I suppose that
with, for example, neuropathic pain, an ongoing local anes-
thetic block is impracticable so the question remains as to
how to block persistent peripheral drives. The recent de-
scription of unique sodium channels in small diameter
peripheral fibres may be a great target (Akopian et al. 1996)
but whether selective blockers can be developed is another
question. These agents would not influence allodynia.
R3. Stopping pain before it starts 
The implications of the degree of peripheral drive for the
concept of pre-emptive analgesia are then developed by
Devor, Gracely, and Cleland & Gebhart. The point
about the need for relentless block for acute pain manage-
ment (Gracely) is borne out by our study (sect. 7.2) in
which the timing of morphine treatment on the formalin
response was used. This is illustrated in Figure R1. I agree
entirely with the points made by Cleland & Gebhart and
illustrated in their diagram. I have been using Figure R1 for
talks (a case for parallel evolution?) because it makes the
same points but also points out that pre-emptive treatments
for tissue injury may also pre-empt beneficial evoked inhi-
Figure R1. Damage to tissue as a result of surgery (but it could
equally apply to inflammation, trauma, or neuropathy) can cause a
baseline level of pain transmission that is enhanced by peripheral
and central mechanisms of hypersensitivity. The activation of
central inhibitory systems will reduce the level of pain transmitted
to higher centres. In the second panel, in the presence of contin-
ued tissue damage, a short lasting preventive agent (with periph-
eral or central actions) will only delay the pain that may occur
without the compensatory inhibitions, which have also been pre-
empted. The third panel shows how preventive and continued
treatment will block all pain until the tissue heals.
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bitions (sect. 7.2). Thus there may be a rebound enhanced
pain after a short-lasting pre-emptive treatment wears off.
In the longer term, patients may do less well if only a brief
pre-emptive block is given. There is some clinical evidence
to support this premise, as discussed by McQuay (1994).
R4. Pains and brains 
Moving centrally into the spinal cord, I indicated that we
understand a reasonable amount about the mechanisms
underlying plasticity in this first relay in pain transmission.
Hardcastle and Watkins & Maier are right: the brain
should not be missing in any overview of pain. Hardcastle
quotes my remark on supraspinal analgesia, but I accept
fully that we need to know much more about pains in the
brains. Benedetti’s comments also related to these points
because he discusses the anxiogenic actions of the peptide
cholecystokinin (CCK). It is interesting to note that CCK
causes anxiety and reduces analgesia. I accept the point
made by Watkins & Maier that the term “anti-opioid” is
too restrictive, yet the papers they cite on the wider role of
CCK in reducing non-opoid analgesia were published only
after my target article.
Han has made many important contributions to the
research on CCK and I welcome the additional points that
he makes in his commentary, all of which I agree with, but I
was unable to mention in my target article because of space
constraints. Noble et al., although they entitle their
account “Clinical perspectives,” discuss pharmacological
studies in rodents. I presume that the clinical aspects relate
to dependence and tolerance. I take exception to their
premise that these are problems with the clinical use of
opiates such as morphine. There is really no evidence that
tolerance is a major problem, since because increased pain
can lead to a need to increase the dose, a condition very
different from tolerance. Likewise, a psychological depen-
dence leading to drug-seeking behaviour is a very rare event
with clinical use of opioids (see McQuay 1997). The ratio-
nale for new opioids does not need to include a problem
that not only does not exist but is a myth that has hindered
the appropriate use of opiates in the clinical use of pain. It
may be possible to cause analgesia via manipulation of
endogenous opioids, but, as is clear from several of the
target articles and commentaries in this BBS issue, an
opiate that works in neuropathic states would be more than
welcome. In this context, CCK antagonists as adjuncts to
morphine might do the trick and NMDA antagonists with
an opiate or other combinations as mentioned might be
appropriate (sects. 5.2 and 7.1).
In response to pain facilitating brain-to-cord messages in
inflammation and illness (Watkins & Maier), I would
respond that this may well occur but the balance is still
tilted toward compensatory inhibitions after inflammation.
Although there are peripheral, spinal, and centrifugal con-
tributions to enhancement of pain and hyperalgesia these
are held down by inhibition. I still stand by my section 7.3
where I suggested that inhibition is increased in inflam-
mation and reduced in neuropathy. Of this point, more
later.
R5. Feelings and pain 
The affective side of pain is obviously important and occurs
in the brain. Yet, the facts that opioids are rewarding and
that noradrenaline and 5HT are intimately linked to mood
and anxiety, and CCK to anxiety, may be telling us some-
thing about the pharmacological modulation of pain and
links between the sensory and affective aspects of pain. It is
revealing that CCK is reduced after inflammation (less
anxiety?) and thus exogenous opioid analgesia is enhanced.
In this situation there is increased descending alpha-2
activity and this increase in noradrenergic transmission
could elevate mood and analgesia. By contrast, in neuropa-
thy, CCK is increased (anxiogenesis?) and opioid controls
are decreased. Add to these the roles of the endogenous
opioids and the anxious enkephalin knockout mouse (Be-
nedetti), and a common pattern may emerge in which
anxiety and pain go together, and euphoria, anxiolysis, and
analgesia go hand in hand, the former in neuropathic states
and the latter in inflammation. Pathology in the case of
nerve damage disrupts both emotions and sensory control;
by contrast, after inflammation, beneficial compensations
occur. As shown by Watkins & Maier, illness and infec-
tions can also impinge upon these systems. So, as discussed
above, I am convinced of the importance of the higher
centres but it is extremely difficult to investigate some of
these events with animal studies due to anaesthesia in
electrophysiological studies and problems of interpretation
in behavioural approaches. The ability to scan the human
brain is most likely to provide the impetus to studies
of brains and pains. However, it must not be forgotten that
the brain responds, in terms of affective and sensory re-
sponses to inputs from the spinal cord. The ability of
peripheral and central events to substantially alter ascend-
ing messages (by increasing or decreasing them) will have a
major impact on what messages arrive in the brain and will
alter the affective nature of the stimulus.
The peripheral and spinal events are important in their
own right, and one need consider only nonmammalian
species. The survival value of the response to a noxious
stimulus is ancient in evolutionary terms and occurs in very
primitive organisms where it is likely to have little or no
affective component (Glanzman 1995; Ghirardi et al.
1995). Understanding the first relays is an essential step
toward understanding the higher consequences.
R6. Controlling pains 
Whilst nestling in the spinal cord, I wish to comment on
Siddall, Clarke, Hu & Sessle, and Omote. The latter
comment really reiterates the points I made in sections 4.4.
and 7.3 regarding the role of inhibition, both amino-acid
and monoamine mediated, and adds some new data. It is
interesting to note the enhanced monoamine systems in
neuropathic states, which must be the one example of an
increase in inhibitions in neuropathic pain. Omote men-
tions the peripheral actions of opioids in inflammation, a
topic I mentioned briefly. Stein & Scha¨fer dilate upon this
topic from a field of study created almost single-handedly
by Stein. I agree entirely that an opioid devoid of central
penetration would be an analgesic in inflammation, but I
would add that the degree of analgesia produced by this
peripheral effect may not be that high and that the control
of inflammatory pain is less of a clinical problem than the
control of neuropathic pain where this peripheral action
may not be so apparent. However, if there is a mixed pain,
inflammatory and neuropathic, or inflammation around a
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damaged nerve, then this tactic may translate to other pain
controls.
Hu & Sessle emphasise that trigeminal mechanisms of
pain, of critical importance not only for dental pain but for
headache, migraine, and trigeminal neuralgia, may share
characteristics with many of the spinal events described. I
agree with all of Hu & Sessle’s points and read with interest
their new findings on the importance of NMDA excitations
and GABA inhibitions in the final determination of trigemi-
nal output.
Clarke brings together various strands and we appear to
be in full agreement with the idea that inhibitions are a
major part of the story. The problem with neuropathic pain
(and Siddall reinforces this point) is that inhibitions may
fail. This may be due in part to neuronal dysfunction
(GABA) and in part to a number of other factors (see sect. 5
of original article). Thus, if opioid controls are reduced in
neuropathic pains, the approach taken is either to reduce
excitations (excitability blockers, membrane stabilizers, and
anticonvulsants) or to enhance monoamine inhibitions by
the use of antidepressants. Clarke’s points reinforce my
own about the complexity of the descending control sys-
tems. However, the number of receptors and the important
point made by Clarke regarding the opposite effects on
motor control means that the chances of producing novel
drugs with selective effects on pain is actually quite high.
In addition to the monoamines, GABA could be a target
(Siddall) and the benzodiazepines may be one way to
enhance inhibitions. However, as we have recently argued,
their use depends on the state of GABAA receptor medi-
ated controls. Benzodiazepines enhance GABA function.
If, as might well be the case, GABA controls are increased
after inflammation, there could be very little increase that
benzodiazepines could induce. Furthermore, in neuro-
pathic pains, if, as several of us have mentioned, there is a
loss of GABA controls, possibly due to neuronal dysfunc-
tion, then there will be no GABA tone to be augmented.
Controlled clinical studies on the use of benzodiazepines
are needed. We have recently reviewed this area of pain
research (Dickenson et al. 1997).
R7. Learning about pain 
The final area covered by the commentaries is that of pain
and learning. Birbaumer & Flor make a number of points,
several of them already addressed earlier in this Response.
Yes, the higher cortical processing of pain is critical and
memories may well be established as a result of painful
experiences, as well as compatible processes occurring in
other sensory modalities. Not only may tinnitus be a facet of
this but we need to consider hallucinations and agnosia as
part of a wide spectrum of pathological and drug induced
alterations in the processing of sensory events in the world
around and within us. I gave the details of combination
therapy for pain because of the multiple pharmacology of
the systems; I and several others (see sect. R2) feel that
there is no central processing without peripheral drive.
The exception to this is central pain. I did not cover this
area because almost nothing is known about it. However, it
may not be correct to consider pain as simply another
sensory modality. As Hardcastle in particular points out,
there is a major psychological component to pain, and in
most people, this is unpleasant. Other sensory modalities,
visual and auditory (see Birbaumer & Flor), are neutral.
These modalities do not elicit a withdrawal reflex either.
The survival value of the stimulus is ancient in evolutionary
terms and occurs in very primitive organisms, as mentioned
earlier. Learning in response to a noxious stimulus can be
demonstrated in aplysia, which has only a few hundred
neurones, but even here, the events are sufficiently com-
plex (Glanzman 199; Ghiradi et al. 1995).
Hole et al. discuss learning with regard to noxious
inputs, but although enhanced responses can occur in
response to an intense stimulation, I feel that the role of
inhibition in controlling these events is of utmost impor-
tance. The four studies Hole et al. cite include two in slices
where most inhibitions may be severed, a neonatal cord,
where inhibitions have not matured and excitations are
greater, and an adult anaesthetized rat. Yes, central en-
hancement of incoming messages could be viewed as a form
of learning, but under these circumstances we find almost
exactly the same results as Randic. Not all spinal nocicep-
tive neurones are facilitated; a number show reduced
responses after peripheral inflammation, indicating com-
pensatory inhibitions (Stanfa et al. 1992). In fact, Hole et
al. only mention one facet of hippocampal function, long
term potentiation (LTP [see also: Shors & Matzel: “Long-
term Potentiation” BBS 20(3) 1997]). It is clear that in
addition to this prolonged potentiation there is also short-
and long-term depression and short-term potentiation. The
latter is common in the spinal cord and depressive mecha-
nisms are likely to hold the former in check. Again, in the
marine mollusc, both short- and long-term potentiation can
occur and inhibition controls the extent of potentiation
(Fischer & Carew 1993; Ghiradi et al. 1995). As proposed in
section 7.3, if these inhibitory mechanisms function nor-
mally in the mammalian spinal cord, pain is held in check, a
sensible modus operandi for a sensory system. In neuro-
pathic pain, where inhibitions may fail, the long-term
hyperalgesias and allodynias dominate. It would be point-
less to have a system in the spinal cord in which the gain is
routinely shifted upward for many days after a brief stimulus.
R8. Conclusions 
Pain is a sensation that is handled differently by the central
nervous system depending on the nature of the stimulus
(affect, reflex-induction, and commonness). The mecha-
nism of peripheral and central sensitization are much more
common and widespread than, for example, tinnitus. Most
humans experience many acute pain states where either or
both of these events are likely to occur (sprained ankles,
sunburn, childbirth, dental surgery, etc.). I appreciate the
comments of Birbaumer & Flor but feel that pain is more
than just another sensory event. There are parallels with
other sensory events and other forms of learning but pain
stands alone as a sensory system. It can be amplified at
peripheral and central sites, where the level of transmission
is controlled by inhibition and where the net end result is
unpleasant. As a result of a series of events at peripheral,
spinal, and higher levels, people suffer pain, they do not
simply perceive it.
